We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Peerport Limited (trading as MultiISA) is targeting the multi-million-pound market and claims to offer a holistic approach to Individual Savings Account (ISA) management. The company asserts that traditional ISA managers don’t give users enough flexibility with their investment choices. Current ISA rules restrict investors to only one ISA of each type per tax year. This impedes the investors’ ability to build a diversified IFISA portfolio. Peerport argues that its portal offers investors the freedom to operate multiple accounts like Innovative Finance ISA (IFISA), Cash ISA, and Stocks & Shares ISA under a single ISA management platform. The company will use the investment to finalise the build-out of its end to end platform, fund its office space, manage marketing costs, oversee staffing costs, pay regulatory fees and supervise working capital.

Pitch Rated

88%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £6,033
Rebel Energy (RE) is an energy supplier on a mission to address inequality and provide everyone with easy access to clean and affordable energy, to eventually eliminate fuel poverty. RE claims that fuel poverty led to 16,500+ cold-related deaths in the UK in 2018. RE argues that as the UK home electricity market enters a phase of growth in a post-COVID world, it will be focused on offering reliable customer service and develop strategies that help people who are struggling with their electricity bills. The company has applied for a B Corporation accreditation. RE asserts that its customer support systems are automated and can handle multiple queries simultaneously. It plans to offer a weekly direct debit payment option. RE will use the investment to grow its business across different verticals.

Pitch Rated

50%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £503,810
Run An Empire is a mobile app that is encouraging people to get outside and start jogging/ running more often using gamification. The idea behind the app is that users run around a particular area and then that area is claimed as their 'territory' until another user jogs that area and then claims it. 
days to go: Expired investment: £60,370
Chip is one of the fastest-growing Fintech companies in the UK. Chip has built an app that uses the user's banking app to make personalised decisions about their money. Its user base has doubled since its previous fundraising in 2018. The company has 153,000 accounts, and it has processed more than £130m of savings. ChipX is the company's revolutionary returns platform and it has a waiting list of more than 50,000 people. The company is a winner of the British Bank Award, 2 Crowdcube awards, and 1 World Banking Award. It has welcomed many management executives from Funding Circle, Monzo, and Purple Bricks. Chip is now scaling with market-leading returns on ChipX. It aims to build the biggest savings account in the world. With the proceeds, the company will double its team and expand ChipX in the €10 trillion European savings market.
days to go: Expired investment: £3,768,260
Using artificial intelligence to accurately match a person's CV with a business's job requirements. Recruitment Smart have developed SniperAI, a tool created by specialists and a researcher from Carnegie Mellon University to quickly search and scan the ideal candidate for a specific job role. This technology can be integrated into a company's job listings to automatically screen submitted CVs and returns a suitability score. In addition, as HR departments are under constant scrutiny to provide information on equality in the workplace, SniperAI can offer a list of appropriate candidates without bias. Recruitment Smart will generate revenue from initial set-up costs and licensing the product to businesses.
days to go: Expired investment: £272,650
We created FlyFit with the aim to change the way people travel. Air travel can be stressful, lonely, and unhealthy. On top of this, with average layovers of 2+ hours, flight delays, and hours waiting in security, there is too much unproductive time in airports with limited healthy options to choose from.
days to go: Expired investment: £500,060
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph